Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R130 in Relapsed/Refractory Bone and Soft Tissue Tumors
NCT05851456Phase 1Recruiting
- Sponsor
- Shanghai Yunying Medical Technology Co., Ltd.
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of R130 in osteosarcoma (OS), soft tissue sarcoma (STS) and Bone tumor (BT), sponsored by Shanghai Yunying Medical Technology Co., Ltd. Primary endpoints: Subject incidence of adverse events at 6 months, Subject incidence of laboratory abnormalities at 1 month and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
R130
03
Conditions
osteosarcoma (OS)soft tissue sarcoma (STS)Bone tumor (BT)
Beyond the preview
Go deeper on NCT05851456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05851456.